Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

26223 reported adverse events

Drugs of this class: EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE DARUNAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE EMTRICITABINE EMTRICITABINE AND TENOFOVIR ALAFENAMIDE EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, AND TENOFOVIR ALAFENAMIDE EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, AND TENOFOVIR DISOPROXIL FUMARATE TRUVADA

These side effects are most commonly reported by patients taking drugs of the Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] class:

# Side effect Count
0 PAIN 1912
1 ANXIETY 1898
2 EMOTIONAL DISTRESS 1672
3 ECONOMIC PROBLEM 1656
4 ANHEDONIA 1565
5 FOETAL EXPOSURE DURING PREGNANCY 1178
6 DRUG INTERACTION 1083
7 DIARRHOEA 967
8 NAUSEA 944
9 RENAL FAILURE 870
See all common reactions for Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

Drugs of the Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 CLOACAL EXSTROPHY 24 0.5581
1 ACUTE HIV INFECTION 75 0.5137
2 BLADDER AGENESIS 25 0.3906
3 HYPERANDROGENISM 21 0.3500
4 SPINOCEREBELLAR DISORDER 13 0.3421
5 FEAR-RELATED AVOIDANCE OF ACTIVITIES 20 0.3226
6 AIDS ENCEPHALOPATHY 18 0.3000
7 CSF VIRUS IDENTIFIED 18 0.2903
8 GASTROINTESTINAL DISORDER CONGENITAL 21 0.2727
9 AIDS DEMENTIA COMPLEX 16 0.2623
See all enriched reactions for Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]